Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda
PSM can be used to create counterfactual groups from other data sources. The best counterfactual group for assessing treatment effect is provided by data collected in the placebo arm of previous trials followed by that from observational data collected concurrently to the current trial (SiVET). Even with PSM, observational data collected prior to the current trial may overestimate treatment effect.
Authors
- Pontiano Kaleebu (ORCID: https://orcid.org/0000-0001-9706-2977)
- Yunia Mayanja (ORCID: https://orcid.org/0000-0002-0414-1818)
- Andrew Abaasa (ORCID: https://orcid.org/0000-0002-6770-5588)
- Eugene Ruzagira (ORCID: https://orcid.org/0000-0002-7291-1693)
- Sylvia Kusemererwa (ORCID: https://orcid.org/0000-0002-1390-109X)
- Zacchaeus Anywaine (ORCID: https://orcid.org/0000-0001-5771-5515)
Institutions
- University of London (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Uganda Virus Research Institute (UG)
Publication Details
- Journal
- Vaccines
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3390/vaccines13080844
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- International AIDS Vaccine Initiative
- U.S. President’s Emergency Plan for AIDS Relief
- European and Developing Countries Clinical Trials Partnership